Millennium Management’s Sigilon Therapeutics, Inc. Common Stock SGTX Stock Holding History

Millennium Management’s Portfolio SGTX Stock Details SGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-21,425	Closed	-$259K	–	7057
2023 Q1	$259K	Buy	21,425 +3,598	+20%	+$37.4K	﹤0.01%	5017
2022 Q4	$81K	Buy	17,827 +105	+0.6%	+$599	﹤0.01%	5648
2022 Q3	$116K	Sell	17,722 -5,997	-25%	-$54.8K	﹤0.01%	5917
2022 Q2	$256K	Buy	+23,719	New	+$319K	﹤0.01%	5492
2022 Q1	–	Sell	-2,868	Closed	-$103K	–	7827
2021 Q4	$103K	Sell	2,868 -8,889	-76%	-$506K	﹤0.01%	6242
2021 Q3	$864K	Buy	+11,757	New	+$905K	﹤0.01%	4842
2021 Q2	–	Sell	-8,008	Closed	-$2.33M	–	7320
2021 Q1	$2.33M	Sell	8,008 -637	-7%	-$253K	﹤0.01%	3392
2020 Q4	$5.4M	Buy	+8,645	New	+$3.92M	﹤0.01%	2365

Other funds holding SGTX

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return

YCM

Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management's SGTX Position: Q2 2023 in Review

Millennium Management sold out of Sigilon Therapeutics, Inc. Common Stock (SGTX) in Q2 2023, closing a stake of 21,425 shares — an estimated $259K sold.

Millennium Management first reported a position in SGTX in Q4 2020 and held it in 8 quarters. The position peaked at $5.4M in Q4 2020. 16 funds tracked by Wall St. Rank hold SGTX as of Q2 2023.

Millennium Management reported no remaining Sigilon Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Millennium Management sold 21,425 Sigilon Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $259K.
Millennium Management first reported a position in Sigilon Therapeutics, Inc. Common Stock in Q4 2020 and held it in 8 quarters.
Millennium Management's Sigilon Therapeutics, Inc. Common Stock position peaked at $5.4M in Q4 2020.
16 funds tracked by Wall St. Rank held Sigilon Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Millennium Management's 13F filing for Q2 2023, filed 14 Aug 2023.